Contents

Search

alosetron (Lotronex)

Withdrawn from US market 11/2000. See Notes: (below) Indications: -> irritable bowel syndrome in women with diarrhea as predominant symptom of >= 6 months duration who have not responded to conventional therapy Adverse effects: 1) constipation (may be severe) 2) ischemic colitis (reason for US market withdrawal) Mechanism of action: -> selective serotonin [5HT]-3 receptor antagonist Notes: - prescribing physicians must be enrolled in the Prescribing Program for Lotronex (PPL) [3] - anatomic & biochemical abnormalities of the GI tract must be excluded - pharmacists can only dispense prescriptions that have a PPL Sticker

Related

irritable bowel syndrome (IBS) serotonin [5HT]-3 receptor

General

gastrointestinal agent

Database Correlations

PUBCHEM correlations

References

  1. Prescriber's Letter 7(8):43 2000
  2. Kaiser Permanente Northern California Regional Drug information update
  3. Prescribing Program for Lotronex (PPL) http://www.lotronex.com/Physicians/Prescribing/ (888) 423-5227